Single‐Dose Pharmacokinetics of Modafinil and Methylphenidate Given Alone or in Combination in Healthy Male Volunteers
- 8 March 1998
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 38 (3) , 276-282
- https://doi.org/10.1002/j.1552-4604.1998.tb04425.x
Abstract
Modafinil is a novel wake‐promoting agent being developed for treatment of excessive daytime sleepiness associated with narcolepsy. An open, 3 × 3 Latin square, randomized, cross‐over study was performed in healthy males to compare the pharmacokinetics of single‐dose oral modafinil (200 mg) and methylphenidate (40 mg) administered alone or in combination. Blood samples were obtained for analysis of d‐ and l‐threo‐methylphenidate and modafinil and its acid and sulfone metabolites. Pharmacokinetic parameters were determined by noncompartmental methods, but could not be evaluated for modafinil sulfone due to plasma levels that were close to the assay quantitation limit. Although sporadic differences in plasma concentrations were observed between treatments, coadministration of modafinil and methylphenidate did not significantly alter the plasma concentrations of modafinil, modafinil acid, modafinil sulfone, or methylphenidate enantiomers compared with administration of these agents alone. Half‐life (t1/2), maximum concentration (Cmax), area under the concentration—time curve (AUC0–∞), total clearance (Cl/F), and apparent volume of distribution (Vd/F) for modafinil and t1/2, Cmax, and AUC0–∞ for modafinil acid were not affected by concomitant administration of methylphenidate. Small but statistically significant increases in time to Cmax (tmax) were observed for modafinil and modafinil acid after methylphenidate coadministration compared with modafinil alone. Modafinil coadministration did not significantly alter the pharmacokinetics of d‐ or l‐threo‐methylphenidate, except for a small decrease in Vd/F of l‐threo‐methylphenidate. Concomitant methylphenidate may cause a delay in the oral absorption of modafinil, but this delay might not be relevant clinically. Coadministration did not alter the extent of oral absorption and disposition of either agent. Therefore, a pharmacokinetic interaction between modafinil and methylphenidate would be unlikely.Keywords
This publication has 12 references indexed in Scilit:
- Modafinil Binds to the Dopamine Uptake Carrier Site with Low AffinitySleep, 1994
- Pharmacokinetics and pharmacodynamics of ( + )-threo-methylphenidate enantiomer in patients with hypersomniaClinical Pharmacology & Therapeutics, 1994
- Effects of Modafinil on Symptomatology of Human NarcolepsyClinical Neuropharmacology, 1993
- Effets du modafinil (300 mg) sur le sommeil, la somnolence et la vigilance du narcoleptiqueNeurophysiologie Clinique, 1993
- Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the catBrain Research, 1992
- Effect of modafinil and amphetamine on the rat catecholaminergic neuron activityNeuroscience Letters, 1991
- Central α1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animalsEuropean Journal of Pharmacology, 1990
- The absorption of sustained‐release methylphenidate formulations compared to an immediate‐release formulationBiopharmaceutics & Drug Disposition, 1989
- PharmacokineticsPublished by Taylor & Francis ,1982
- EVALUATION of SHORT-TERM and LONG-TERM TREATMENT of the NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDEActa Neurologica Scandinavica, 1976